

Member Associations
Members of IFRA Committees
cc RIFM
Members of the JAG
Downstream Users Associations

25 September 2025

Information Letter 1217

Subject: Terpinyl Acetate Multiconstituent (EC 904-693-9)

Related ILs:

Dear Colleagues,

With this Information letter we would like to inform you on a recent ECHA decision regarding the testing of Terpinyl Acetate Multiconstituent (EC 904-693-9) as required by REACH Annex IX.

In 2023, the Lead Registrant submitted, as part of the required REACH registration dossier updates, a testing proposal for an OECD 443 (Extended One Generation Reproductive Toxicity Study). Upon review of the existing data, ECHA has now ruled that no further animal testing is allowed and that the Lead Registrant should self-classify the substance as CMR 1B (Fertility and Development) based on the results of existing screening studies (OECD 408 combined with OECD 421, and an OECD 414). We expect this decision to be published on the ECHA dissemination site¹ in the next months.

Following this decision, the LR has brought this issue to the attention of the IFRA CMR&ED WG, and they will share all data on Terpinyl Acetate Multiconstituent in full to enable a thorough critical review and to gather any suggestions for potential additional data generation.

This process is expected to continue throughout most of 2025 and 2026 with the aim of reaching a conclusion on the GHS classification in time for inclusion in the IFRA/IOFI Labelling Manual to be published in January 2027. **Until then, the Lead Registrant does not intend to change the current self-classification of Terpinyl Acetate Multiconstituent (no CMR 1B).**

However, given the potential implications of ultimately having to follow the CMR 1B self-classification decision by ECHA, the Lead Registrant considered it prudent to inform all stakeholders in advance. We would further like to remind you that self-classifications in the EU have **no direct regulatory impact**. The safe use of this material remains unaltered as per the existing RIFM Safety Assessment.

¹ <https://echa.europa.eu/information-on-chemicals/dossier-evaluation-status/-/dislist/details/0b0236e1893157e2>

Furthermore, this decision on Terpinyl Acetate Multiconstituent (EC 904-693-9) does not impact the classification or registration of Alpha Terpinyl Acetate (mono constituent), which is registered under a separate REACH registration dossier (EC 201-265-7, CAS 80-26-2).

We will continue to keep you informed throughout 2026, via additional information letters, regarding the ongoing review by the IFRA CMR&ED WG and their conclusions.

If you have any further questions, please contact Cristina Arregui (carrequi@ifrafragrance.org) at IFRA.

Best regards,
IFRA